NEUROVIVE PHARMACEUTICAL AB has a total of 132 patent applications. It decreased the IP activity by 94.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), Canada and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are PHARMA MAR SA, SCIFLUOR LIFE SCIENCES INC and UCB PHARMA GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 15 | |
#2 | Canada | 12 | |
#3 | Republic of Korea | 11 | |
#4 | WIPO (World Intellectual Property Organization) | 11 | |
#5 | China | 10 | |
#6 | Mexico | 10 | |
#7 | Australia | 9 | |
#8 | United States | 7 | |
#9 | Brazil | 6 | |
#10 | Israel | 6 | |
#11 | Singapore | 6 | |
#12 | EAPO (Eurasian Patent Organization) | 5 | |
#13 | Hong Kong | 5 | |
#14 | Chile | 4 | |
#15 | South Africa | 4 | |
#16 | Serbia | 3 | |
#17 | Japan | 2 | |
#18 | Taiwan | 2 | |
#19 | Jordan | 1 | |
#20 | Morocco | 1 | |
#21 | New Zealand | 1 | |
#22 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Environmental technology | |
#5 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Gregory Matthew Alan | 51 |
#2 | Hansson Magnus Joakim | 49 |
#3 | Moss Steven James | 48 |
#4 | Elmer Eskil | 42 |
#5 | Moss Steven | 36 |
#6 | Ehinger Karl Henrik Johannes | 34 |
#7 | Wilkinson Barrie | 31 |
#8 | Elmér Eskil | 23 |
#9 | Batcheller Derek Gregory | 13 |
#10 | Hansson Magnus | 12 |
Publication | Filing date | Title |
---|---|---|
KR20190077476A | Uses of phosglycerin macrocyclic analogs as anticancer compounds | |
MX2019005675A | Liver prodrugs of mitochondrial proton ionophores. | |
WO2017060418A1 | Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases | |
WO2017060400A1 | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions | |
WO2017060422A1 | Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders | |
KR20160143731A | Prodrugs of succinic acid for increasing atp producion | |
SG11201607908QA | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation | |
WO2015155231A1 | Novel cell-permeable succinate compounds | |
WO2014053617A1 | Mitochondrial toxicity test | |
EP2903609A1 | Protected succinates for enhancing mitochondrial atp-production | |
ZA201302141B | Cyclosporine emulsion | |
JO3063B1 | Novel compound and methods for its production | |
CA3028414A1 | Sanglifehrin derivatives and methods for their production |